HM Payson & Co. cut its holdings in Sanofi SA (NYSE:SNY) by 6.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 37,740 shares of the company’s stock after selling 2,710 shares during the quarter. HM Payson & Co.’s holdings in Sanofi were worth $1,686,000 as of its most recent filing with the SEC.
Other hedge funds have also added to or reduced their stakes in the company. Girard Partners LTD. acquired a new position in shares of Sanofi in the third quarter valued at about $154,000. Stratos Wealth Partners LTD. acquired a new stake in Sanofi during the third quarter worth about $174,000. Quantum Capital Management acquired a new stake in Sanofi during the third quarter worth about $202,000. Holderness Investments Co. acquired a new stake in Sanofi during the third quarter worth about $204,000. Finally, Nisa Investment Advisors LLC acquired a new stake in Sanofi during the third quarter worth about $205,000. Institutional investors and hedge funds own 7.34% of the company’s stock.
A number of equities research analysts have issued reports on the stock. UBS Group reiterated a “neutral” rating on shares of Sanofi in a research note on Friday. Argus increased their price objective on shares of Sanofi from $48.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, November 8th. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Thursday, November 1st. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research note on Wednesday, October 31st. Finally, Wolfe Research assumed coverage on shares of Sanofi in a research note on Tuesday, October 23rd. They set a “market perform” rating on the stock. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. Sanofi has an average rating of “Hold” and an average price target of $49.50.
Sanofi (NYSE:SNY) last posted its earnings results on Wednesday, October 31st. The company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.09. The firm had revenue of $9.39 billion during the quarter, compared to analysts’ expectations of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.71 earnings per share. On average, analysts predict that Sanofi SA will post 3.09 EPS for the current fiscal year.
In other news, major shareholder Sanofi sold 104,552 shares of the stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “HM Payson & Co. Decreases Position in Sanofi SA (SNY)” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2018/12/01/hm-payson-co-decreases-position-in-sanofi-sa-sny.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Article: Hedge Funds
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.